BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of “Moderate Buy” from Analysts

BioNTech SE (NASDAQ:BNTX) has been given a consensus rating of “Moderate Buy” by the sixteen analysts that are currently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $138.67.

A number of brokerages recently issued reports on BNTX. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. TD Cowen lowered their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and raised their price objective for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft upped their target price on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, September 19th. Finally, Berenberg Bank began coverage on shares of BioNTech in a report on Tuesday, November 19th. They issued a “buy” rating and a $130.00 price target for the company.

BioNTech Price Performance

BNTX opened at $118.39 on Wednesday. The company has a market capitalization of $28.38 billion, a price-to-earnings ratio of -56.38 and a beta of 0.26. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $113.81 and a 200-day moving average price of $98.73. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same period in the previous year, the business earned $0.73 EPS. BioNTech’s revenue was up 38.9% compared to the same quarter last year. Equities analysts expect that BioNTech will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently modified their holdings of BNTX. Baillie Gifford & Co. lifted its position in BioNTech by 0.4% in the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after buying an additional 31,773 shares during the last quarter. FMR LLC raised its stake in shares of BioNTech by 797.8% during the third quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after acquiring an additional 5,598,190 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioNTech by 4.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 594,000 shares of the company’s stock worth $47,734,000 after acquiring an additional 24,426 shares during the last quarter. Candriam S.C.A. boosted its stake in shares of BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after purchasing an additional 418,695 shares in the last quarter. Finally, Fred Alger Management LLC bought a new position in shares of BioNTech during the 3rd quarter valued at $59,485,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.